D Calne
Overview
Explore the profile of D Calne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beaman B, Canfield D, Anderson J, Pate B, Calne D
Med Microbiol Immunol
. 2000 Aug;
188(4):161-8.
PMID: 10917152
Nocardia asteroides GUH-2 (GUH-2) invades the nigrostriatal region of the brain in mice [15]. Selective dopaminergic neuronal dropout in the substantia nigra results in parkinsonian changes characterized by movement disorders...
2.
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, et al.
Mov Disord
. 1999 Dec;
14(6):911-3.
PMID: 10584663
No abstract available.
3.
Perl D, Olanow C, Calne D
Ann Neurol
. 1998 Sep;
44(3 Suppl 1):S19-31.
PMID: 9749570
Alzheimer's disease (AD) and Parkinson's disease (PD) are generally considered to be separate and distinct disease entities. However, a considerable amount of evidence demonstrates that these disorders share common clinical...
4.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R, et al.
Neurology
. 1996 Jul;
47(1):1-9.
PMID: 8710059
To improve the specificity and sensitivity of the clinical diagnosis of progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski syndrome), the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for...
5.
Gasser T, Wszolek Z, Supala A, Trofatter J, Ozelius L, Uitti R, et al.
Adv Neurol
. 1996 Jan;
69:87-95.
PMID: 8615189
No abstract available.
6.
Hertzman C, Wiens M, Snow B, Kelly S, Calne D
Mov Disord
. 1994 Jan;
9(1):69-75.
PMID: 8139607
We compared personal histories of 127 cases and 245 controls to identify possible environmental risk factors for idiopathic parkinsonism (IP). Of our controls, 121 had cardiac disease (CD) and 124...
7.
Olanow C, Calne D
Neurology
. 1992 Apr;
42(4 Suppl 4):13-26; discussion 41-8.
PMID: 1584429
Selegiline monotherapy has been clearly demonstrated to delay the development of disability in early, otherwise untreated Parkinson's disease patients. It remains uncertain, however, whether this benefit is due to protective...
8.
Eisen A, Calne D
Can J Neurol Sci
. 1992 Feb;
19(1 Suppl):117-23.
PMID: 1571856
Features common to amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD) are reviewed. Shared epidemiological aspects include an increasing frequency which is proportional for each disease. We...
9.
Eisen A, Siejka S, Schulzer M, Calne D
Electroencephalogr Clin Neurophysiol
. 1991 Jun;
81(3):209-15.
PMID: 1710970
Peak-to-peak measurement of the maximum amplitude motor evoked potential (MAXMEP) elicited by 20 consecutive transcranial magnetic stimuli recorded from the contracting thenar and hypothenar muscles measured 9.8 +/- 2.0 mV...
10.
Rajput A, Calne D, Lang A
Can J Neurol Sci
. 1991 Feb;
18(1):87-92.
PMID: 1674670
A National Conference on Parkinson's disease was held on September 7th-8th, 1990 in Victoria, British Columbia. The scientific program included 11 formal presentations, 10 small group workshops and video presentations...